10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TRIM11 Antibody (C-Term)

Peptide-affinity purified goat antibody
Catalog # AF2326a

Specification

TRIM11 Antibody (C-Term) - Product Information

Application	**IHC**
Primary Accession	Q96F44
Other Accession	NP_660215.1, 81559
Reactivity	**Human**
Host	**Goat**
Clonality	**Polyclonal**
Concentration	**0.5 mg/ml**
Isotype	**IgG**
Calculated MW	**52774**

TRIM11 Antibody (C-Term) - Additional Information

Gene ID 81559

Other Names
E3 ubiquitin-protein ligase TRIM11, 6.3.2.-, Protein BIA1, RING finger protein 92, Tripartite motif-containing protein 11, TRIM11, RNF92

Format
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
TRIM11 Antibody (C-Term) is for research use only and not for use in diagnostic or therapeutic procedures.

TRIM11 Antibody (C-Term) - Protein Information

Name TRIM11 {ECO:0000303|PubMed:16904669, ECO:0000312|HGNC:HGNC:16281}

Function
E3 ubiquitin-protein ligase that promotes the degradation of insoluble ubiquitinated proteins, including insoluble PAX6, poly-Gln repeat expanded HTT and poly-Ala repeat expanded ARX (By similarity). Mediates PAX6 ubiquitination leading to proteasomal degradation, thereby modulating cortical neurogenesis (By similarity). May also inhibit PAX6 transcriptional activity, possibly in part by preventing the binding of PAX6 to its consensus sequences (By similarity). May contribute to the regulation of the intracellular level of HN (humanin) or HN-containing proteins through the proteasomal degradation pathway (By similarity). Mediates MED15 ubiquitination leading to

proteasomal degradation (PubMed:16904669). May contribute to the innate restriction of retroviruses (PubMed:18248090). Upon overexpression, reduces HIV-1 and murine leukemia virus infectivity, by suppressing viral gene expression (PubMed:18248090). Antiviral activity depends on a functional E3 ubiquitin-protein ligase domain (PubMed:18248090). May regulate TRIM5 turnover via the proteasome pathway, thus counteracting the TRIM5-mediated cross-species restriction of retroviral infection at early stages of the retroviral life cycle (PubMed:18248090). Acts as an inhibitor of the AIM2 inflammasome by promoting autophagy-dependent degradation of AIM2 (PubMed:27498865). Mechanistically, undergoes autoubiquitination upon DNA stimulation, promoting interaction with AIM2 and SQSTM1/p62, leading to AIM2 recruitment to autophagosomes (PubMed:27498865).

Cellular Location
Cytoplasm. Nucleus

Tissue Location
Ubiquitous..

TRIM11 Antibody (C-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

TRIM11 Antibody (C-Term) - Images



AF2326a (4 µg/ml) staining of paraffin embedded Human Kidney. Steamed antigen retrieval with

citrate buffer pH 6, HRP-staining.

TRIM11 Antibody (C-Term) - References

The tripartite motif family identifies cell compartments. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A. EMBO J. 2001 May 1;20(9):2140-51. PMID: 11331580